Register to chat with like-minded investors on our interactive forums.
Period:
Draw Mode:
| Volume | 0 |
|
|||||
| News | - | ||||||
| Day High | Low High |
||||||
| Day Low | |||||||
| Company Name | Stock Ticker Symbol | Market | Type |
|---|---|---|---|
| Syndax Pharmaceuticals Inc | SNDX | NASDAQ | Common Stock |
| Price Change | Change Percent | Stock Price | Last Traded
|
|
|---|---|---|---|---|
| 0.00 | 0.00% | 20.57 | 08:31:50 |
| Open Price | Low Price | High Price | Close Price | Prev Close |
|---|---|---|---|---|
| 20.57 |
| Trades | Volume | Avg Volume | 52 Week Range |
|---|---|---|---|
| 0 | 0 | - | 11.215 - 25.34 |
| Last Trade Time | Type | Quantity | Stock Price | Currency |
|---|---|---|---|---|
| - | 0 | $ 20.57 | USD |
Syndax Pharmaceuticals (SNDX) Options Flow Summary
Syndax Pharmaceuticals Inc Financials
| Market Cap | Shares in Issue | Float | Revenue | Profit/Loss | EPS | PE Ratio |
|---|---|---|---|---|---|---|
| 1.75B | 84.97M | - | 0 | -209.36M | -2.46 | - |
| Short Interest | Dividends Per Share | Dividend Yield | Ex-Div Date | Insider B/S | Insider % Owned |
|---|---|---|---|---|---|
| - | - | - | - |
Syndax Pharmaceuticals News
Loading Messages....
|
|
{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}} |
Loading Messages....
Historical SNDX Price Data
| Period | Open | High | Low | VWAP | Avg. Daily Vol | Change | % |
|---|---|---|---|---|---|---|---|
| 1 Week | 20.41 | 21.54 | 20.13 | 20.83 | 686,520 | 0.16 | 0.78% |
| 1 Month | 23.67 | 24.375 | 20.13 | 21.95 | 889,243 | -3.10 | -13.10% |
| 3 Months | 20.83 | 25.34 | 20.085 | 22.67 | 1,091,847 | -0.26 | -1.25% |
| 6 Months | 11.99 | 25.34 | 11.96 | 19.86 | 1,357,208 | 8.58 | 71.56% |
| 1 Year | 21.08 | 25.34 | 11.215 | 18.51 | 1,292,153 | -0.51 | -2.42% |
| 3 Years | 15.32 | 29.86 | 11.215 | 19.36 | 861,365 | 5.25 | 34.27% |
| 5 Years | 6.81 | 29.86 | 5.35 | 18.85 | 693,237 | 13.76 | 202.06% |
Syndax Pharmaceuticals Description
| Syndax Pharmaceuticals Inc is a clinical stage biopharmaceutical company focused on developing a pipeline of combination therapies in multiple cancer indications. The company's product candidates are entinostat which has direct effects on both cancer cells and immune regulatory cells, SNDX-6352 and SNDX-6352, an anti-CSF-1R monoclonal antibody, to enhance the body's immune response on tumors that have shown sensitivity to immunotherapy. Business activity of the group is primarily functioned through the region of United States. |
